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ABSTRAK
Latar belakang: infeksi saluran kemih (ISK) sering ditangani dalam praktek sehari-hari sebagai overactive 
bladder (OAB) dengan memberikan antikolinergik yaitu pilihan pengobatan yang direkomendasikan untuk OAB. 
Namun aplikasi antikolinergik untuk menghilangkan gejala ISK belum pernah diteliti. Sepengetahuan kami, 
penelitian ini merupakan uji klinis pertama yang menyelidiki penggunaan antikolinergik dalam pengobatan 
ISK. Penelitian ini bertujuan mengevaluasi apakah terapi tambahan antikolinergik bersama antibiotik empiris 
bermanfaat mengurangi gejala dan aman bagi wanita dengan ISK non-komplikata. Metode: penelitian ini berupa 
uji acak terkendali tersamar ganda terhadap wanita berusia >18 tahun dengan ISK non-komplikata. Pasien diacak 
untuk menerima solifenacin succinate 5 mg (kelompok 1) atau plasebo (kelompok 2) sebagai tambahan terhadap 
terapi empiris levofloxacin 500 mg selama 3 hari. Pasien dengan kelainan struktural dan/atau fungsional, dan 
dengan riwayat reaksi alergi dieksklusi dari penelitian. Kami mengobservasi perubahan overactive bladder symptom 
score (OABSS), skor patient perception of bladder condition (PPBC), gejala lain yang dilaporkan pasien, serta 
efek samping yang dialami. Hasil: sebanyak 126 pasien, 63 untuk masing-masing kelompok, memulai penelitian 
ini dengan median usia 44 (19-67) tahun. Tidak didapatkan perbedaan usia, OABSS, dan skor PPBC di antara 
kedua kelompok pada awal penelitian. Kedua kelompok menunjukkan penurunan bermakna (p<0,05) OABSS 
dan skor PPBC di akhir terapi; namun besar penurunan di antara keduanya tidak berbeda. Pada kelompok 1 
didapatkan 22,2% pasien mengeluhkan mulut kering, 3,2% konstipasi, 25,4% mual, dan 4,7% mengantuk. Pada 
kelompok 2 didapatkan 20,0% pasien mengeluhkan mulut kering, 21,7% mual, dan 3,3% mengantuk. Satu pasien 
pada kelompok 2 mengalami reaksi alergi sehingga dikeluarkan dari penelitian. Kesimpulan: tidak didapatkan 
perbedaan bermakna penurunan OABSS dan skor PPBC dengan menambahkan antikolinergik bersama antibiotik 
empiris pada wanita dengan ISK non-komplikata. Tidak ditemukan adanya efek samping serius pada studi ini.
Kata kunci: skor overactive bladder symptom (OABSS), patient perception of bladder condition (PPBC), 
solifenacin succinate, ISK tanpa komplikasi.
ABSTRACT
Background: urinary tract infection (UTI) is often treated in daily practice as overactive bladder (OAB) by 
giving anticholinergic, the recommended treatment options of OAB. However, anticholinergic application for UTI 
symptoms relief has never been investigated. To our knowledge, this study was the first randomized trial which 
investigate anticholinergic use for UTI treatment. This study aimed to evaluate whether additional anticholinergic 
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is beneficial alongside an empiric antibiotic therapy in reducing symptoms and tolerable for females with 
uncomplicated UTI. Methods: this was a randomized double-blind controlled trial that included female aged >18 
y.o with uncomplicated lower UTI. Patients were randomly assigned to either solifenacin succinate 5 mg (group 
1) or placebo (group 2) in addition to empiric levofloxacin 500 mg treatment for 3 days. Those with structural 
and/or functional abnormalities of the urinary tract and allergic reaction history were excluded. We observed 
changes in overactive bladder symptom score (OABSS), patient perception of bladder condition (PPBC) score, 
patient-reported symptoms and adverse events. Results: a total of 126 patients, 63 for each group, initiated the 
trial with median age of 44 (19-67) y.o. There were no differences of age, OABSS, and PPBC score between the 
2 groups at baseline. We found significant (p<0.05) reduction of OABSS and PPBC score in both groups at the 
end of therapy; however the amount of reduction were not different between groups. In group 1 we found 22.2% 
of patients complained of dry mouth and 25.4%, 4.7%, 3.2% of patients complained of nausea, somnolence and 
constipation respectively. In group 2 we found 20.0%, 21.7% and 3.3% patients who complained of dry mouth, 
nausea, and somnolence respectively. One patient in group 2 experienced allergic reaction and was dropped out. 
Conclusion: we found no significant difference in OABSS and PPBC score reduction by adding anticholinergic to 
antibiotic therapy for females with uncomplicated UTI. There was no serious adverse event recorded.
Keywords: overactive bladder symptom score (OABSS), patient perception of bladder condition (PPBC), 
solifenacin succinate, uncomplicated UTI.
INTRODUCTION
Urinary tract infection (UTI) is a common 
health problem for females in which half of them 
suffered from it once in a lifetime.1,2 It becomes the 
most common non-intestinal infection suffered by 
females worldwide,3 while in developing countries 
its prevalence varies between 10-40%.4,5 Acute 
uncomplicated lower UTI was frequently found 
in healthy, non-pregnant, adult female with no 
other anatomical or functional abnormalities of 
the urinary tract.6 In spite of its low morbidity, 
uncomplicated UTI may result in daily activity 
disturbance2 and cost burden.7
Empiric antibiotics remain as standard 
treatment for uncomplicated UTI with 
bothersome urinary tract symptoms and has 
been reported to be cost-effective.8 Nevertheless, 
in some patients the symptoms are not relieved 
at the end of treatment. UTI Symptoms (e.g. 
dysuria, frequency, urgency), which mimic the 
storage symptoms of overactive bladder (OAB), 
sometimes remain to interfere with women’s daily 
routines. Several treatment strategies aside from 
extending antibiotic duration have been proposed 
to deal with UTI symptoms without rising 
resistance.9 Due to its similar symptoms, UTI is 
often treated in daily practice as OAB by giving 
anticholinergic, the recommended treatment 
options of OAB.10 However anticholinergic 
application for UTI symptoms relief has never 
been investigated. To our knowledge, this study 
was the first randomized trial which investigate 
anticholinergic use for UTI treatment.
We aimed to evaluate whether additional 
anticholinergic therapy alongside an empiric 
antibiotic therapy is beneficial and tolerable 
in reducing symptoms in females with 
uncomplicated lower UTI.
METHODS
This trial recruited female aged more than 
18 y.o with acute or recurrent uncomplicated 
lower UTI who came to our hospital’s urology 
outpatient clinic. Diagnosis was made based on 
history of the disease, physical examination, 
and laboratory findings. A simple questionnaire 
sheet was used to record specific data, including 
age, duration of symptoms, episode of infection, 
and other comorbidities. We used overactive 
bladder symptom score (OABSS)11 and patient 
perception of bladder condition (PPBC)12 tools 
to assess severity of the symptoms. All patients 
were provided with clean urine container to 
collect midstream urine samples.
We diagnosed UTI in female who suffered 
from at least one of the symptoms (dysuria, urinary 
frequency, nocturia, urgency)13 accompanied with 
one of the following urinalysis criteria: five or more 
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white blood cells per high power field (HPF) on 
microscopic analysis,14 positive bacteria, positive 
nitrite or leucocyte-esterase test on dipstick.15 
We ruled out those with indwelling catheter, 
pregnancy, history of urinary tract structural or 
functional abnormalities, preexisting disorder of 
the bladder (stone, mass), sexually transmitted 
disease (urethritis, vaginitis, genital herpes), 
neurologic disorder, and allergic reaction history 
toward levofloxacin or solifenacin succinate.
Study Outcome
We assessed OABSS and PPBC score before 
intervention began as baseline. Then OABSS and 
PPBC were measured each day during treatment 
and after completion of treatment. Patient-
reported symptoms and adverse event were also 
noted. We observed changes in the OABSS and 
PPBC score compared to baseline.
Sample Size
Number of needed samples was calculated 
using statistical formula based on OABSS 
difference at the end of therapy between the 
two groups that is considered significant by the 
investigator (delta OABSS = 2). Sixty patients of 
each groups were needed to achieve confidence 
interval of 95% and statistical power of 80%.
Randomization and Blind
Our study was a double blind randomized 
controlled trial, in which the evaluator did not 
know about the category of subject groups. The 
study participants were recruited by urologists 
or urology residents in duty. Eligible subjects 
were randomly assigned (1:1 ratio) with 
permuted block methods (block sizes 4) using 
online random number generator in sequentially 
concealed numbered envelopes to receive one of 
the following treatments orally once daily for a 
period of 3 days: solifenacin succinate 5 mg and 
levofloxacin 500 mg (group 1) or placebo and 
levofloxacin 500 mg (group 2). All the drugs 
were given in similar preparation. We used 
quinolone drug class to treat UTI according to 
antibiotic sensitivity pattern in our hospital.16 
Patient and physician were blinded toward given 
drug.
Statistical Analysis
Data was analyzed using a computer 
software stastical program of SPSS version 
22.0. Analysis was performed per protocol to 
compared group 1 versus group 2, for which the 
trial was powered at 95%. Chi-square analysis 
was used to compare proportion of marital 
status. When the data did not meet Chi-square 
criteria we used Fisher test. Bivariate numerical 
analyses of age, OABSS and PPBC score were 
performed using unpaired student t-test when the 
data in both groups showed normal distribution 
or mann-whitney rank test when it did not show 
normal distribution. We used paired sample t-test 
to compare OABSS and PPBC score changes in 
each groups between days, when distribution 
showed inhomogenous data we used wilcoxon 
test. The level of significance used was based on 
a two-sided p<0.05.
Study Protocol
The consent to participate in the study 
was obtained by signing the written informed 
consent. This trial has been approved by Faculty 
of Medicine, Universitas Indonesia / Cipto 
Mangunkusumo Hospital Health Research Ethics 
Committee (574/PT02.FK/ETIK/2011) and 
registered at ClinicalTrials.gov (NCT02094703).
RESULTS
We randomized 63 patients into group 1 
(anticholinergic and antibiotic) while another 
63 patients were allocated into group 2 (placebo 
+ antibiotic) as shown in Figure 1. There were 
no differences of age, marital status, level of 
education, OABSS and PPBC score between the 
two groups at baseline (Table 1). Three patients 
in group 2 were dropped out at final assessment 
(4 days after initial therapy). During the study 
there was one patient who refused to consume 
medication, one patient who lost the given 
drugs, while the third patient suffered from rash 
allergic reaction. Thus we performed per protocol 
analysis.
Frequency (53.2%) and urgency (46.8%) 
were the two most common symptoms suffered by 
the patients. Whereas only 8 (6.3%) patients who 
suffered from hematuria at initial presentation 
(Table 1).
Group 1 resulted in lower OABSS tendency 
compared to group 2 in all study day. A lower 
PPBC score was always found in group 1 
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Figure 1. Flowchart of the study
Table 1. Baseline characteristics of the study population
Variables Total (n=126) Group 1 (n=63) Group 2 (n=63)
Age* (years old), mean 
(SD); median (range)
42.18 (13.94);
44.00 (19.00-67.00) 
43.16 (12.94);
45.00 (20.00-67.00)
41.21 (14.92);
42.00 (19.00-66.00)
Marital Status, n (%)
 - Married 99 (78.6) 53 (84.1) 46 (73.0%)
 - Single 27 (21.4) 10 (15.9) 17 (27.0%)
Level of Educationƚ, n (%)
 - Low 70 (55.6) 40 (63.5) 30 (47.6%)
 - High 56 (44.4) 23 (36.5) 33 (52.4%)
OABSS*, mean (SD); 
median (range)
4.20 (3.97);
3.00 (0.00-20.00)
3.46 (3.12);
2.00 (0.00-11.00)
4.94 (4.57);
3.00 (0.00-20.00) 
PPBC Score*, mean (SD); 
median (range)
1.88 (1.61);
2.00 (0.00-5.00)
1.73 (1.54);
1.00 (0.00-5.00)
2.03 (1.67);
2.00 (0.00-5.00)
Symptoms suffered, n (%)
 - Nocturia 53 (42.1)
 - Hematuria 8 (6.3)
 - Lower abdominal pain 45 (35.7)
 - Urgency 59 (46.8)
 - Frequency 67 (53.2)
 - Dysuria 53 (42.1)
* Inhomogeneous
ƚ Low education means high school or lower. High education means diploma degree or higher.
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(Table 2). All the two groups showed significant 
(p<0.05) reduction in OABSS and PPBC score at 
the end of therapy compared to baseline. Lower 
symptoms score reflects less symptoms suffered.
Significant OABSS and PPBC reduction 
in each groups were also found since the first 
day of treament and continued until the end of 
observation. However, when we compare the 
reduction amount of OABSS and PPBC score 
before and after treatment, a non-significant 
results between the groups were shown (Table 2). 
Adverse Event
In group 1 we found 22.2% patients who 
suffered from dry mouth and 25.4%, 4.7%, 3.2% 
of patients suffered from nausea, somnolence and 
constipation respectively. There was no patient 
in group 1 who suffered from allergic reaction 
(Figure 2).
In group 2 we found 20.0%, 21.7% and 3.3% 
patients who suffered from dry mouth, nausea, 
and somnolence respectively. One patient in 
group 2 suffered from allergic reaction due to 
antibiotic then dropped out from the study. There 
was no patient in group 2 who suffered from 
constipation.
DISCUSSION
Uncomplicated UTI is considered as a rapid 
recovery disease. On the third day after doctors’ 
treatment, most cystitis patients were free of 
Table 2. Comparison of OABSS and PPBC score between groups based on day of treament
OABSS PPBC Score
Group 1 (n=63) Group 2 (n=60) p value Group 1 (n=63) Group 2 (n=60) p value
Initial* 3.46 (3.12) 4.94 (4.57) 1.73 (1.54) 2.03 (1.67)
2.00 (0.00-11.00) 3.00 (0.00-20.00) 1.00 (0.00-5.00) 2.00 (0.00-5.00)
Day I* 2.30 (2.67) 3.33 (3.76) 1.25 (1.41) 1.70 (1.52)
1.00 (0.00-9.00) 2.00 (0.00-13.00) 1.00 (0.00-5.00) 2.00 (0.00-4.00)
Day II * 1.65 (2.62) 2.73 (3.12) 0.92 (1.30) 1.38 (1.42)
1.00 (0.00-12.00) 1.00 (0.00-12.00) 0.00 (0.00-4.00) 1.00 (0.00-4.00)
Day III * 1.18 (2.13) 2.25 (2.90) 0.68 (1.15) 1.07 (1.33)
0.00 (0.00-9.00) 1.00 (0.00-12.00) 0.00 (0.00-4.00) 0.00 (0.00-4.00)
Day IV* 0.83 (1.74) 1.43 (2.43) 0.41 (0.93) 0.68 (1.17)
0.00 (0.00-9.00) 1.00 (0.00-11.00) 0.00 (0.00-4.00) 0.00 (0.00-4.00)
Delta* -2.63 (2.52) -3.55 (3.79) p = 0.293 -1.32 (1.29) -1.37 (1.31) p = 0.864
-2.00 (-8.00-1.00) -2.00 (-19.00-1.00) (Mann-Whitney) -1.00 (-4.00-0.00) -1.00 (-4.00-0.00)
(Mann-
Whitney)
* Inhomogeneous
Figure 2. Proportion of adverse events
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symptoms as shown in a Scandinavian study.17 
Another study in Korean population reported a 
median of 2.40 days for symptoms improvement 
among simple cystitis patients after antibiotic 
treatment, however 15.3% patients were 
considered as failure of treatment.18 We proposed 
anticholinergic as an add-on therapy to empiric 
antibiotic in treating uncomplicated lower 
UTI. Anticholinergic was chosen considering 
its effect to reduce storage symptoms in OAB 
patients. Storage symptoms, one of the lower 
urinary tract symptoms (LUTS) spectrum, have 
been identified as bothersome symptoms in 
patients with UTI. Based on our knowledge this 
was the first study that analyzed utilization of 
anticholinergic for LUTS treatment caused by 
infection.
Antibiotic treatment is recommended in 
many guidelines to be given by primary care 
providers when someone was suspected with 
UTI.19-21 In our study levofloxacin was used 
as standard treatment. Fluoroquinolone is 
antimicrobial agent known for its broad spectrum 
activity against gram-positive and gram-negative 
bacteria.22 It works by trapping DNA gyrase and 
topoisomerase IV as complexes thus damaging 
DNA strands and inhibiting bacterial growth.23 
Bacterial colonization and inflammation of 
the urothelium was thought as etiology of LUTS 
in some women with UTI.24 Storage LUTS were 
considered dominant in UTI patients. A study 
revealed that many molecular changes (increased 
purinergic signaling and high levels of NO) in 
bladder induced cystitis may lead to detrusor 
overactivity with lower bladder capacity, lower 
compliance, and decreased micturition interval.25 
Acute cystitis may result in 83.33% rate of 
detrusor instability in rat model study.26 Inflamed 
bladder was found to induce hyperactivity and 
reduce micturition volume-pressure threshold.27 
An acute irritant infection increases the number 
of bladder mucosa and submucosa afferent C 
fibers thus enhanced sensitivity to incoming 
stimuli which manifested in frequent micturition, 
urgency, dysuria, and other LUTS.26 It was shown 
that cystitis condition caused down-regulation 
of bladder muscarinic and purigenic receptors 
that related to cholinergic and purigenic nervous 
activity.28
It has been suggested that anticholinergic 
inhibit the binding of acetyhcholine, the primary 
contractile neurotransmitter at muscarinic 
receptors M2 and M3 on detrusor smooth 
muscle cells and bladder wall, eventually reduce 
spontaneous myocyte activity during storage 
phase. The results are decreasing in frequency 
and intensity of detrusor contractions.29,30 Those 
findings made anticholinergic a promising 
substance for UTI treatment. Solifenacin 5 mg 
was chosen as our main investigation subject 
since it showed the least adverse event in clinical 
practice,31 and its balance between efficacy and 
tolerability.32
Different treatment strategies have been 
proposed to improve symptoms resolution.33 
A non-inferiority study showed that ibuprofen 
gives similar symptoms free results comparable 
with antibiotic. Ibuprofen was considered as 
an alternative treatment due to its analgesia 
and inflammatory activity.34 Symptoms relieve 
became the target therapy for UTI since 
bacteriuria may remain asymptomatic.
Our study reported symptoms resolutions 
for both treatment arms after 3 days as shown 
in OABSS and PPBC score reduction. Even in 
the first day of treatment significant OABSS 
reduction were found in group 1 and 2: -1.16 and 
-1.65 respectively when compared to baseline. At 
the end of study, we found 58.7% patients in group 
1 and 44.4% in group 2 did not have symptoms 
anymore. These results were similar to study 
conducted in Lower Saxony Germany which 
showed 51.5% completely free of symptoms 
patients after 3 days antibiotics treatment in 
women with uncomplicated UTI.34 A Cochrane 
Database Systematic Review concluded that 3 
days antibiotic therapy was considered enough to 
achieve symptomatic cure during uncomplicated 
UTI treatment in women while 5-10 days could 
be considered in obtaining bacteriological 
cure.35 We found significant improvement in all 
urinalysis parameter including bacteriuria after 
3 days treatment; unfortunately our tools did not 
enable to show quantitative assay.
This  present  s tudy fai led to  show 
anticholinergic additional benefit in reducing 
storage symptoms induced by infection origin. 
Both group 1 and 2 showed significant reduction 
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of OABSS and PPBC score every day to the 
end of therapy, however when we compared 
derivation amount of each other the result was 
not significant. We think that this condition 
might be caused by self-limiting nature of 
uncomplicated UTI that made additional drug 
unnecessary. Another reason might be related to 
duration of anticholinergic administration until a 
therapeutic response emerges. A study in tertiary 
center in Taiwan toward OAB patients recorded 
3 months median time was needed to show 
OABSS improvement;36 while meta-analysis also 
indicated 12 weeks as time required to reduce 
the symptoms after initiating anticholinergic.32 
The most common adverse event to deal with 
anticholinergic consumption was gastrointestinal 
disorder;31 in our study we found 2 patients with 
constipation and 16 patients with nausea after 
one day treatment of solifenacin however these 
results did not differ significantly when compared 
to placebo group.
The weaknesses of our study are lack of 
non-antibiotic treatment arm, and no urine 
culture evidence. We suggest a further research 
conducted with similar scheme in patients with 
recurrent UTI or complicated UTI demanding 
a longer period of treatment. In those kinds of 
patients additional drugs might give more value.
CONCLUSION
In this study, we found no significant 
symptoms resolution as shown in no difference 
of OABSS and PPBC score reduction by adding 
anticholinergic to empiric antibiotic therapy 
compared to empiric antibiotic therapy alone for 
females with uncomplicated lower UTI. There 
was no serious adverse event recorded for adding 
anticholinergic to antibiotic therapy.
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